A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of the study drug ixekizumab
compared to ustekinumab in participants with moderate-to-severe-plaque psoriasis.